Incannex to call a Pre-IND meeting after successful animal study for proprietary IHL-675A. IHL-675A suppressed inflammation > CBD in IHL’s human cell and animal studies.

2020-11-24 03:17:48 (AET) by Ring Zhang   582


Incannex Healthcare (ASX: IHL) has resumed its second day elevated trading volume following the announcement of positive IHL-675A in vivo (animal) results on the potency of its anti-inflammatory action.

Incannex Healthcare (ASX: IHL) has resumed its second day elevated trading volume following the announcement of positive IHL-675A in vivo (animal) results on the potency of its anti-inflammatory action.

The drug candidate IHL-675A, which is a combination drug including cannabidiol (CBD), is a potential treatment for sepsis-associated acute respiratory distress syndrome (‘SAARDS’), the leading cause of mortality related to COVID-19. And, now it is thought that it could be used for a range of other conditions in which inflammation is a problem.

The clinical stage cannabinoid development company announced that the in vivo examination conducted in Taiwan laboratories confirms previously announced in vitro data demonstrating that IHL-675A exhibits stronger anti-inflammatory properties than alone.

The results of the in vivo study are presented in Figure 1, showing the optimal fixed dose IHL-675A combination assessed for each cytokine in 11 groups of 10 mice. The bars noted as ‘Predicted CBD + HCQ’ represent IHL’s expectation based on the activity of each drug alone. The observed results from the study significantly exceeded the predicted results across the inflammatory cytokines analysed.

text

text
(Figure 1)

Results from in vitro studies, which the company announced on ASX last week, have already showed that IHL-675A outperformed cytokine inhibition by CBD by 109% to 767% after 24 hours from drug administration across a range of inflammatory cytokines. The observed data from the in vivo study has validated result.

As a result of the extremely positive data in both in vitro and in vivo studies, IHL has expanded its IP strategy to pursue patent protection for the treatment of broad range of other inflammatory diseases.

Next Step for FDA Pathway

IHL has engaged Camargo Pharmaceutical Services to call a Pre-Investigational New Drug (Pre-IND) meeting with the FDA for the use of IHL-675A in the treatment of patients with SAARDS.

The Pre-IND meeting will provide IHL the ability to seek advice from the FDA on the most efficient development plan required to submit an IND application and initiate in human clinical trials in the United States. Specifically, Camargo will assist IHL to develop the nonclinical, clinical, pharmacological, and biopharmaceutical strategy to be proposed to FDA.

IHL expects to receive an expedited meeting with FDA because the company intends to request emergency use Authorisation for IHL-675A to treat patients with COVID-19.


Source: IHL ASX announcement


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
金矿勘探商DTM宣布完成维州项目钻探计划

维州金矿商Dart Mining NL(ASX:DTM)之前宣布的2020年钻探计划现已完成。尽管维州COVID-19封锁造成严厉的操作限制,但Dart表示,仍可以安全地完成春季期间(潮湿)在陡峭、半高山地形上的4个钻探计划,总计5,000米钻探深度。

cover
金矿勘探商MKR的MT BOPPY项目勘探计划进展更新

金矿勘探商Manuka Resources Limited(ASX:MKR)发布Mt Boppy金矿最近钻探的最新情况。团队正在进行针对Mt Boppy金矿资源的潜在资源扩展工作,但先前宣布的Mt Boppy矿山3D模型以及最近完成的矿山品位控制计划中的反循环钻探(RC)都有助于更好地了解当前设计坑底和下方的高品位矿化程度。

相关文章

cover
脱水研报 - 澳大利亚锂钴矿开采业与MIN、GXY和PLS

本周新能源汽车概念股异常火爆,特斯拉市值突破8000亿美元,马斯克成为全球首富。应 61 Financial VIP 用户的要求,本周研究的对象为澳大利亚电池材料矿产开采行业,所涉及的公司包括:Mineral Resources 、Galaxy 和 Pilbara 。

cover
珠宝零售连锁店 Michael Hill 半年度利润同比增长30%至40%

珠宝零售连锁店 Michael Hill International Limited (ASX: MHJ) 早间发布公告称,在截至2020年12月27日的21财年半年度业绩表现中,预计息税前利润为5600万澳元至6000万澳元,同比增长30%至40%。在此期间,所有市场和渠道同店销售额稳步增长,其中同店销售额同比增长6.3%,而截止12月季度同比增长5.6%,澳大利亚部门的表现尤为突出。